Publicaciones en colaboración con investigadores/as de Hospital Costa Del Sol (9)

2021

  1. The mutational load and a T-cell inflamed tumour phenotype identify ovarian cancer patients rendering tumour-reactive T cells from PD-1+ tumour-infiltrating lymphocytes

    British Journal of Cancer, Vol. 124, Núm. 6, pp. 1138-1149

2019

  1. Daratumumab in combination with urelumab to potentiate anti-myeloma activity in lymphocyte-deficient mice reconstituted with human NK cells

    OncoImmunology, Vol. 8, Núm. 7

  2. Prophylactic TNF blockade uncouples efficacy and toxicity in dual CTLA-4 and PD-1 immunotherapy

    Nature, Vol. 569, Núm. 7756, pp. 428-432

2018

  1. Association between PD1 mRNA and response to anti-PD1 monotherapy across multiple cancer types

    Annals of Oncology, Vol. 29, Núm. 10, pp. 2121-2128

  2. Interferon gamma, an important marker of response to immune checkpoint blockade in non-small cell lung cancer and melanoma patients

    Therapeutic Advances in Medical Oncology, Vol. 10

  3. International Symposium: Trailblazing in Cancer Immunotherapy, October 29–31, 2017, Pamplona, Spain

    Cancer Immunology, Immunotherapy

2017

  1. Anti-CD137 and PD-1/PD-L1 antibodies en route toward clinical synergy

    Clinical Cancer Research, Vol. 23, Núm. 18, pp. 5326-5328

  2. Pembrolizumab for advanced melanoma: experience from the Spanish Expanded Access Program

    Clinical and Translational Oncology, Vol. 19, Núm. 6, pp. 761-768

2015

  1. Frequency and characteristics of familial melanoma in Spain: The FAM-GEM-1 study

    PLoS ONE, Vol. 10, Núm. 4